Retatrutide vs Palmitoyl Tetrapeptide-7
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. |
| Best For |